_car-t-cell-therapy-and-bites-for-myeloma-preview-1.jpg "CAR T-cell therapy and BiTEs for myeloma from car t vs bite in all Video Screenshot Preview 1")
Gallery_car-t-cell-therapy-and-bites-for-myeloma-preview-3.jpg "CAR T-cell therapy and BiTEs for myeloma from car t vs bite in all Video Screenshot Preview 3")
Gallery_car-t-cell-therapy-and-bites-for-myeloma-preview-hqdefault.jpg "CAR T-cell therapy and BiTEs for myeloma from car t vs bite in all Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 3 minutes 17 seconds
👁 View: 86 times
Play Audio:👁 View: 86 times
Description:
VJHemOnc – Video Journal of Hematology u0026 HemOnc
VJHemOnc – Video Journal of Hematology u0026 HemOnc
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_bispecific-t-cell-engagers-bites-as-treatment-of-b-cell-lymphoma.webp "ASCOcancer")
_the-benefits-of-bispecific-antibodies-over-car-t-cell-therapy-in-lymphoma.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 6 minutes 23 seconds 👁 1.2K
_corporate-bulltalk-original-song.webp "Corporate BullTalknnNo one understands anything you saynYou could put that in your résumé nTake a healthy bite of your corporate spoonnStep in line and sing this tunennCorporate BullTalkn(Keeps me alive)nCorporate BullTalkn(Credit cards)nCorporate BullTalkn(Read the fine print)nCorporate BullTalkn(Get the fucking hint)nnIf your elevator pitch won’t get it upnSomeone's gotta be going downnA working class hero is some kinda freaknLike a song n dancing bird with a foot in its beaknnWhen you wer")
_flt3-directed-car-t-vs-flt3-directed-bite-in-preclinical-aml-model.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_bite-therapy-followed-by-hsct-vs-car-t-cells-in-young-patients-with-r-r-all.webp "Prof Hervé Dombret speaks to ecancer at the 2020 ALL Assembly meeting about the use of BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL.nnHe believes that one of the main questions surrounding these approaches is 'which do we use first?' and also 'can we use one and then another?' as they are sometimes targeting the same antigen.nnProf Dombret explains that one of the key questions for CAR T-cell therapy is how it can be used to induce a new remission in the relapsed")
⏲ 2 min 27 sec ✓ 22-Jan-2020
_car-t-cell-therapy-how-does-it-work.webp "Dana-Farber Cancer Institute")
_the-car-t-cell-strategy-vs-bispecific-antibodies.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_car-t-cell-therapy-and-bites-for-myeloma.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_bispecific-t-cell-engagers-bites-as-treatment-of-b-cell-lymphoma.jpg)
_the-benefits-of-bispecific-antibodies-over-car-t-cell-therapy-in-lymphoma.jpg)
_corporate-bulltalk-original-song.jpg)
_flt3-directed-car-t-vs-flt3-directed-bite-in-preclinical-aml-model.jpg)
_bite-therapy-followed-by-hsct-vs-car-t-cells-in-young-patients-with-r-r-all.jpg)
_car-t-cell-therapy-how-does-it-work.jpg)
_the-car-t-cell-strategy-vs-bispecific-antibodies.jpg)
_car-t-cell-therapy-and-bites-for-myeloma.jpg)
![[+]](/images/menu.gif){kind=small}